According to a new study, testosterone therapy may reduce non-alcoholic fatty liver disease in obese
2021-05-25
(Press-News.org) Press release - Abstract 481: Effects of testosterone therapy on morphology and grade of NAFLD in obese men with functional hypogonadism and type 2 diabetes
According to a new study, testosterone therapy may reduce non-alcoholic fatty liver disease in obese men with functional hypogonadism and type-2 diabetes.
Testosterone therapy may help obese men with functional hypogonadism and type-2 diabetes reduce the prevalence of non-alcoholic fatty liver disease (NAFLD), according to a study being presented at the 23rd?European Congress of Endocrinology (e-ECE 2021), on Tuesday 25 May 2021 at 14:00 CET (http://www.ece2021.org). The two-year study found that therapy with testosterone undecanoate normalised testosterone levels, reduced NAFLD, and suppressed the symptoms of hypogonadism in men living with these conditions.
NAFLD is emerging as a public health issue worldwide. It is estimated that prevalent cases will increase 21% by 2030, from 83.1 million to 100.9 million. NAFLD is more commonly found in people with type-2 diabetes, and is linked to obesity, insulin resistance and atherogenic dyslipidemia. NAFLD refers to excess fat accumulation in the liver, in the absence of excessive alcohol consumption. Alcohol consumption of less than 30 g (3.75 units) per day for men is used as the cut-off to diagnose NAFLD. As an increasing global health issue, this study and its findings may be a promising area for further research.
Dr Kristina Groti Antonic and her team from the University of Ljubljana, Slovenia, carried out a large study on the effects of testosterone therapy on glycemic control, metabolic parameters, vascular function and morphology in obese men with hypogonadism and type-2 diabetes mellitus. They presented a part of this study at e-ECE 2021 in which they evaluated the effects of testosterone therapy on morphology and grade of NAFLD in this population. The two-year clinical trial saw 55 males with functional hypogonadism and type-2 diabetes participate. The first year focused on a double blind, placebo-controlled study and the following year was used for follow-up.
During the study, the participants were randomised into two groups. The first group received testosterone undecanoate during both years of the study, while the second group received a placebo in the first year and testosterone therapy in the second year. A range of tests including testosterone levels, prostate specific antigen and routine blood tests were assessed at the beginning of the trial, 12 and 24 months. Liver ultrasounds for NAFLD grade assessments were performed at the beginning and after two years, which showed an improvement in NAFLD grades after two years of the trial.
Dr Kristina Groti Antonic shared that, "improvement of NAFLD grade was a result of improved insulin resistance, reduction in body mass index and body weight, along with changes in body composition. As we know, testosterone increases lean body mass at the expense of fat mass, either alone or in combination with behavioral and lifestyle modifications. Testosterone with its anti-inflammatory effects also reduced chronic inflammatory state in the liver. Our study shows that testosterone therapy could be used as a suitable therapy for obese men living with non-alcoholic fatty liver disease, and therefore the findings can be used to tackle this growing pandemic."
This knowledge could help obese men living with functional hypogonadism and type-2 diabetes experience normalised testosterone levels and reduced prevalence of non-alcoholic fatty liver disease.
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2021-05-25
Newly published papers further elucidate the mechanisms underlying pridopidine's neuroprotective properties through activation of the Sigma-1 Receptor (S1R).
Pridopidine enhances mitochondrial function and reduces mHTT-induced ER stress, which are impaired in HD, mediated by the S1R.
Three new peer-reviewed publications highlight pridopidine's therapeutic potential and provide data supporting the role of the S1R in neurodegenerative diseases
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, ...
2021-05-25
COLUMBUS, Ohio - A comprehensive analysis of 437 studies from around the world provides the best evidence to date that narcissism is an important risk factor for both aggression and violence, researchers said.
The link between narcissism and aggression was found for all dimensions of narcissism and for a variety of types of aggression. Results were similar regardless of gender, age, whether they were college students, or country of residence.
And, to have an impact, narcissism doesn't have to be at levels so high as to be pathological. Findings showed ...
2021-05-25
Two articles published online today by Alzheimer's & Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer's Association, show substantial changes in the focus and funding of clinical trials for Alzheimer's disease therapies. The newly published articles throw a greater spotlight on a decision -- now before the U.S. Food and Drug Administration (FDA) -- that would potentially bring a new drug therapy to Alzheimer's patients for the first time in nearly 20 years.
Researchers analyzed clinicaltrials.gov, the U.S. National Library of Medicine's database, and five years of annual Alzheimer's pipeline reviews published by UNLV School of Integrated Health Sciences research professor Jeffrey L. Cummings ...
2021-05-25
Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.
The COVID-19 pandemic has lasted more than a year and continues to impact our lives tremendously. Although some countries have launched speedy vaccination campaigns, many still await large-scale immunization schemes and effective antiviral therapies - before that happens, the world urgently needs to regain a semblance ...
2021-05-25
While we sleep, the brain produces particular activation patterns. When two of these patterns - slow oscillations and sleep spindles - gear into each other, previous experiences are reactivated. The stronger the reactivation, the clearer will be our recall of past events, a new study reveals.
Scientists have long known that slow oscillations (SOs) and sleep spindles - sudden half-second to two-second bursts of oscillatory brain activity - play an important role in the formation and retention of new memories.
But experts in the UK and Germany have discovered that the precise combination of SOs and sleep spindles is vital for opening windows during which ...
2021-05-25
As devices continue to be built on an increasingly small scale, scientists are looking toward developing ways to engineer materials at the atomic level. In a breakthrough that will contribute to this, published in Nature Communications, researchers from the RIKEN Cluster for Pioneering Research and RIKEN Center for Advanced Photonics, along with collaborators, have developed a way to use a "dry transfer technique"--a technique that uses no solvent--to position optical quality carbon nanotubes in a precise way.
Carbon nanotubes are a promising type of materials with potential uses in applications such as light-emitting diodes, ...
2021-05-25
HOUSTON - (May 25, 2021) - Sometimes things are a little out of whack, and it turns out to be exactly what you need.
That was the case when orthoferrite crystals turned up at a Rice University laboratory slightly misaligned. Those crystals inadvertently became the basis of a discovery that should resonate with researchers studying spintronics-based quantum technology.
Rice physicist Junichiro Kono, alumnus Takuma Makihara and their collaborators found an orthoferrite material, in this case yttrium iron oxide, placed in a high magnetic field showed uniquely tunable, ultrastrong interactions between magnons in the crystal.
Orthoferrites ...
2021-05-25
PULLMAN, Wash. - Before the huge potential of tiny nanocarriers for highly targeted drug delivery and environmental clean-up can be realized, scientists first need to be able to see them.
Currently researchers have to rely on attaching fluorescent dyes or heavy metals to label parts of organic nanocarrier structures for investigation, often changing them in the process. A new technique using chemically-sensitive "soft" X-rays offers a simpler, non-disruptive way of gaining insight into this nano-world.
In a study published by Nature Communications, a research team demonstrates the capability of the X-ray method on a smart drug delivery nanoparticle and a polysoap nanostructure intended to capture crude oil spilled in the ocean.
"We have developed a ...
2021-05-25
Ancient Judeans commonly ate non-kosher fish surrounding the time that such food was prohibited in the Bible, suggests a study published in the peer-reviewed journal Tel Aviv.
This finding sheds new light on the origin of Old Testament dietary laws that are still observed by many Jews today. Among these rules is a ban on eating any species of fish which lacks scales or fins.
The study reports an analysis of ancient fish bones from 30 archaeological sites in Israel and Sinai which date to the more than 2,000-year span from the Late Bronze Age (1550-1130 ...
2021-05-25
Emergency department visits for common conditions such as appendicitis, miscarriage, gallbladder attacks and ectopic pregnancy decreased markedly at the start of the COVID-19 pandemic, but patient outcomes were not worse, found research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.202821.
"These findings are reassuring, as patients who required emergency care in the first wave of the pandemic continued to present to the emergency department, received similar care and had similar outcomes to patients presenting in the prepandemic period," writes Dr. David Gomez, a trauma surgeon at St. Michael's Hospital, Unity ...
LAST 30 PRESS RELEASES:
[Press-News.org] According to a new study, testosterone therapy may reduce non-alcoholic fatty liver disease in obese
